SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company’s mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy is under Priority Review by U.S. Food and Drug Administration. Ms. Dac will also be responsible for driving continued sales growth of Omeros’ commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution 1%/0.3%), the only drug of its kind approved for use during cataract and lens replacement surgery.
“With the restoration of reimbursement for OMIDRIA, the expected launch of narsoplimab and the impressive and cutting edge assets in our pipeline, the opportunities for commercial success are tremendous. I look forward to leading Omeros’ commercial efforts to capitalize on those opportunities.”
“We’re pleased that Nadia has joined our senior leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Nadia has already hit the ground running, and her high-caliber expertise is a welcome and timely addition at this important juncture in our company’s development. The breadth and depth of her U.S. and global commercial experience as a strategic leader will be a valuable asset to Omeros as we look ahead to bringing our second product to market and advancing our diverse pipeline.”
With deep expertise spanning all commercial functions including marketing, market access and promotion, sales, pipeline management, business development and partnerships, Ms. Dac brings almost three decades of international experience building teams and launching products as a strategic commercial leader at large and small biopharmaceutical companies. She joins Omeros from her most recent role as the chief commercial officer at Alder Pharmaceuticals where she built the commercial team to launch Vyepti® in the migraine prevention market, which later was acquired by Lundbeck. Before joining Alder, she served as vice president of global specialty commercial development at AbbVie where she led the therapeutic area and business development strategies for neuroscience, virology, hepatology, renal, cystic fibrosis and women’s health. Prior to AbbVie, Nadia held several roles of increasing responsibility at Novartis, building the commercial organization that successfully launched Gilenya® and Extavia®. Before Novartis, Nadia led marketing for Biogen’s multiple sclerosis products Tysabri® and Avonex® and for Pfizer’s Alzheimer’s product Aricept®. She also spent several years in positions of increasing responsibility at Johnson & Johnson and Eli Lilly where she started her career in marketing and sales.
“I am excited to be part of the strong leadership team at Omeros,” said Ms. Dac. “With the restoration of reimbursement for OMIDRIA, the expected launch of narsoplimab and the impressive and cutting edge assets in our pipeline, the opportunities for commercial success are tremendous. I look forward to leading Omeros’ commercial efforts to capitalize on those opportunities.”
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a rolling biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3 inhibitor OMS906, which targets the complement system’s alternative pathway, recently entered the clinic, and the company’s PDE7 inhibitor OMS527 has successfully completed its Phase 1 trial. Omeros’ pipeline holds a diverse group of preclinical programs including a novel antibody-generating technology and a proprietary GPCR platform through which it controls 54 new GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing small-molecule GPR174 inhibitors. For more information about Omeros and its programs, visit www.omeros.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely”, “look forward to,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “prospects,” “scheduled,” “should,” “slated,” “targeting,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros’ investigational product, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with product commercialization and commercial operations, unproven preclinical and clinical development activities, financial condition and results of operations, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by our Quarterly Reports on Form 10-Q filed with the SEC and subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
Source Read More